SCHEMBL19962015

SCHEMBL19962015

CN(C(=O)[C@H](Cc1cc(F)cc(F)c1)NC(=O)c1cccc(S(=O)(=O)N[C@@H](Cc2cc(F)cc(F)c2)C(=O)N(C)c2ccc3scnc3c2)c1)c1ccc2sccc2c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.37
PIN1 Q13526 1/20 0.35
LMNA P02545 1/20 0.34
F2 P00734 3/20 0.33
MAPT P10636 1/20 0.33
MAPK1 P28482 1/20 0.33
KDM4E B2RXH2 2/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
PYGL P06737 1/20 0.32
BACE1 P56817 1/20 0.32
AURKA O14965 1/20 0.32
SIRT2 Q8IXJ6 1/20 0.31
PKM P14618 1/20 0.31
HTR2B P41595 1/20 0.31
CTSB P07858 1/20 0.30
CTSS P25774 1/20 0.30
CTSK P43235 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18180358 0.94 ALDH1A1 (0.41) ALDH1A1PIN1LMNAF2MAPT
SCHEMBL18180421 0.94 ALDH1A1 (0.41) ALDH1A1PIN1LMNAF2MAPT
SCHEMBL19962038 0.91 PIN1 (0.39) ALDH1A1PIN1MEN1KMT2APYGL
SCHEMBL19962027 0.89 KMT2A (0.33) F2KMT2APYGL
SCHEMBL18180142 0.85 AURKA (0.39) ALDH1A1PIN1MEN1KMT2APYGL
SCHEMBL18180233 0.85 AURKA (0.39) ALDH1A1PIN1MEN1KMT2APYGL
SCHEMBL19962042 0.85 PYGL (0.34) PIN1PYGLAURKATAS1R3TAS1R1
SCHEMBL19962046 0.85 BACE1 (0.34) PIN1PYGLBACE1TAS1R3TAS1R1
SCHEMBL19962064 0.84 PIN1 (0.36) PIN1MEN1KMT2ASMN1; SMN2PYGL
SCHEMBL19962013 0.84 PYGL (0.34) PIN1PYGLTAS1R3TAS1R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180072997-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BRISTOL-MYERS SQUIBB COMPANY 2018-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180072997-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION EIF2AK2, POLR2H, POLR2E ALDH1A1 2545/4885PIN1 1030/4885LMNA 3382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.